A phase II study of the combination of cyclophosphamide, prednisone and rituximab (CPR) in children, adolescents and young adults With B-lymphocyte Antigen CD20 positive post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation (SOT)

Trial Profile

A phase II study of the combination of cyclophosphamide, prednisone and rituximab (CPR) in children, adolescents and young adults With B-lymphocyte Antigen CD20 positive post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation (SOT)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2014

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Methylprednisolone; Prednisone
  • Indications Post-transplant lymphoproliferative disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Dec 2013 Status changed from completed to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 03 Dec 2013 Planned End Date changed from 1 Mar 2009 to 1 Oct 2009, according to ClinicalTrials.gov record.
    • 28 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top